EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-6.19%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.09B
AUM Growth
+$1.09B
(-9.9%)
Cap. Flow
-$52.6M
Cap. Flow
% of AUM
-4.84%
Top 10 Holdings %
Top 10 Hldgs %
50.97%
Holding
109
New
9
Increased
26
Reduced
34
Closed
23
Top Buys
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$39.1M |
| 2 |
GSK
GSK
|
$30.5M |
| 3 |
Masimo
MASI
|
$30.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$17.3M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$16.8M |
Top Sells
| 1 |
McKesson
MCK
|
$25.7M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$23.5M |
| 3 |
United Therapeutics
UTHR
|
$17.9M |
| 4 |
Envista
NVST
|
$13.6M |
| 5 |
AstraZeneca
AZN
|
$13.5M |
Sector Composition
| 1 | Healthcare | 94.41% |
| 2 | Industrials | 3.35% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Illumina
ILMN
$15.8B
| $13.5M | 1.04% | +38,759 | New | +$13.5M |
|
27
Xenon Pharmaceuticals
XENE
$2.98B
| $12.5M | 0.96% | 410,021 +200,502 | +96% | +$6.13M |
|
28
Icon
ICLR
$13.8B
| $11.4M | 0.87% | 46,816 -5,051 | -10% | -$1.23M |
|
29
Centene
CNC
$14.3B
| $10M | 0.77% | 119,170 -105,443 | -47% | -$8.88M |
|
30
Labcorp
LH
$23.1B
| $10M | 0.77% | 37,910 -7,612 | -17% | -$2.01M |
|
31
Liquidia Corp
LQDA
$2.38B
| $9.89M | 0.76% | 1,377,490 -70,408 | -5% | -$506K |
|
|
NSTG
32
DELISTED
NanoString Technologies, Inc.
NSTG
| $9.75M | 0.75% | 280,695 +15,000 | +6% | +$521K |
|
33
HealthEquity
HQY
$7.72B
| $9.72M | 0.75% | 144,140 -189,212 | -57% | -$12.8M |
|
|
TARO
34
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $9.53M | 0.73% | 220,286 +39,135 | +22% | +$1.69M |
|
35
Qiagen
QGEN
$10.1B
| $9.44M | 0.73% | 192,699 +30,165 | +19% | +$1.48M |
|
36
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.63M | 0.66% | 52,871 -17,369 | -25% | -$2.84M |
|
|
OCDX
37
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $8.3M | 0.64% | 445,059 -441,081 | -50% | -$8.23M |
|
38
argenx
ARGX
$43.6B
| $7.3M | 0.56% | 23,142 +1,646 | +8% | +$519K |
|
39
Repligen
RGEN
$6.88B
| $6.87M | 0.53% | 36,521 +31,937 | +697% | +$6.01M |
|
|
SYNH
40
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $6.59M | 0.51% | 81,416 -4,196 | -5% | -$340K |
|
41
Ionis Pharmaceuticals
IONS
$6.79B
| $5.88M | 0.45% | 158,806 -225,983 | -59% | -$8.37M |
|
42
Zentalis Pharmaceuticals
ZNTL
$122M
| $4.62M | 0.36% | 100,187 +37,024 | +59% | +$1.71M |
|
43
Exelixis
EXEL
$10.1B
| $4.61M | 0.35% | 203,156 -332,544 | -62% | -$7.54M |
|
44
iRhythm Technologies
IRTC
$5.46B
| $4.26M | 0.33% | 27,047 -46,122 | -63% | -$7.26M |
|
45
908 Devices
MASS
$226M
| $4.13M | 0.32% | +217,149 | New | +$4.13M |
|
46
Puma Biotechnology
PBYI
$254M
| $4.1M | 0.32% | 1,424,650 +306,752 | +27% | +$883K |
|
47
Gossamer Bio
GOSS
$562M
| $3.25M | 0.25% | 374,723 +334,813 | +839% | +$2.91M |
|
48
Viridian Therapeutics
VRDN
$1.5B
| $2.88M | 0.22% | 155,743 -38,846 | -20% | -$718K |
|
49
AnaptysBio
ANAB
$569M
| $2.82M | 0.22% | 114,165 -68,447 | -37% | -$1.69M |
|
|
RDUS
50
DELISTED
Radius Health, Inc.
RDUS
| $2.67M | 0.2% | +302,172 | New | +$2.67M |
|